Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.41), may not compare to the analyst estimate of ($0.29). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $2.4 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.